Datamonitor Newswire

Datamonitor Newswire

Comprehensive Real-Time News Feed for Datamonitor.

Results 1 - 11 of 11 in Datamonitor

  1. Can-Fite BioPharma Completes Patient Enrolment For Its Phase II Study ...Read the original story

    Tuesday Aug 8 | BioSpace

    ... to NexavarA and other drugs under development for HCC which have shown to induce hepato-toxicity. According to Datamonitor, the market for hepatocellular carcinoma drugs is projected to reach $1.4 billion in 2019. NexavarA annual sales, as reported ...

    Comment?

  2. 'The UK is unprepared to feed its own people'Read the original story w/Photo

    Jun 22, 2017 | Silicon Alley Insider

    ... if the UK leaves the customers union. The cost of strawberries, for example, could jump by as much as 50%, Datamonitor said. "The UK's exit from the European single market is expected to result in changes in tariffs in food trade between the UK and ...

    Comment?

  3. Minerva Biotechnologies Corporation Announces Outcome Of End-Of-Phase II Meeting With FDARead the original story

    May 14, 2017 | BioSpace

    ... disabling conditions worldwide for young adults and affects more than 21 million people worldwide. According to Datamonitor, an independent market research firm, in 2016 approximately 3.3 million people suffered from schizophrenia in the United ...

    Comment?

  4. Cardiome Pharma Corp. Announces Commercial Launch Of Xydalba (Dalbavancin) In FranceRead the original story

    Mar 2, 2017 | BioSpace

    ... them to choose how to manage therapy based on their patients' needs and availability of resources." According to Datamonitor, the diagnosed incidence of ABSSSI was ~155,000 patients in 2012 and is expected to grow to over 176,000 by 2030.2 The ...

    Comment?

  5. Cardiome Announces Commercial Launch of Xydalba (dalbavancin) in FranceRead the original story w/Photo

    Mar 3, 2017 | PR Newswire

    ... them to choose how to manage therapy based on their patients' needs and availability of resources." According to Datamonitor, the diagnosed incidence of ABSSSI was ~155,000 patients in 2012 and is expected to grow to over 176,000 by 2030.2 The ...

    Comment?

  6. Swiss Biotech Relief Therapeutics to Consolidate Offices and Cut Jobs, CEO and CFO Step DownRead the original story

    Feb 19, 2017 | BioSpace

    ... neuropathy. The peripheral diabetic neuropathy market is estimated to reach $4.1 billion in 2019, according to Datamonitor. RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and is headquartered in Zurich, ...

    Comment?

  7. CSL's hemophilia drug approved for sale in EuropeRead the original story w/Photo

    Jan 9, 2017 | Korea Herald

    ... set to present a new treatment option for European patients with hemophilia A. According to market research firm Datamonitor, the market for hemophilia A in the top five European Union member states -- Germany, the UK, France, Spain and Italy -- ...

    Comment?

  8. Cardiome Pharma Corp. Announces Commercial Launch Of XYDALBA (Dalbavancin) In GermanyRead the original story

    Dec 19, 2016 | BioSpace

    ... their patients fully recognize the benefits offered by XYDALBA as shown in the DISCOVER1 trials." According to Datamonitor, the diagnosed incidence of ABSSSI was ~216,000 patients in 2012 and is expected to grow to over 300,000 by 2030.2 The German ...

    Comment?

  9. Card Payments Just Surpassed Cash. That's Good, Right? Part 3Read the original story w/Photo

    Dec 12, 2016 | Finextra Research news

    ... in light of Russia having the most active number of e-wallet users of any country in the world, according to Datamonitor. In India, Paytm's e-wallet was the initial beneficiary of de-monetization and the ensuing migration from cash. Within a few ...

    Comment?

  10. Cardiome Pharma Corp. Announces Commercial Launch Of Xydalba (Dalbavancin) In The UKRead the original story

    Dec 7, 2016 | BioSpace

    ... them to choose how to manage therapy based on their patients' needs and availability of resources." According to Datamonitor, the diagnosed incidence of ABSSSI was ~280,000 patients in 2012 and is expected to grow to over 400,000 by 2030.2 The UK ...

    Comment?

  11. Firebird Artisan Mills set to expand gluten-free ancient grain businessRead the original story w/Photo

    Oct 18, 2016 | Bakery & Snacks

    Earlier data from Datamonitor showed that chia and quinoa led the field in US gluten-free product launches that contain ancient grains. It indicated that new US food launches containing ancient grains or seeds have almost tripled between the period of 2008 and 2014.

    Comment?